CD28 and KIR2D receptors as sensors of the immune status in heart and liver transplantation

Human Immunology

Volumn 72, Issue 10, 2011, Pages 841-848

  Blanco Garcia R M ^a   Lopez Alvarez M R ^a   Garrido, I P ^a   Salgado Cecilia, G ^a   Campillo, J A ^a   Bolarin J M ^a   Legaz, I ^a   Muro, M ^a   Garcia Alonso A M ^a   Martinez Sanchez M V ^a   de la Pena Moral J M ^a   Pascual Figal, D A ^a   Alvarez Lopez M R ^a   Miras, M ^a   Minguela, A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

CD28; CMV; HCV; Heart transplantation; KIR2D; Liver transplantation

Indexed keywords

CD28 ANTIGEN; GANCICLOVIR; IMMUNOGLOBULIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2D; LAMIVUDINE; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; FLOW CYTOMETRY; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

ANTIGENS, CD28; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, KIR; SPAIN; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION;

EID: 80052969839     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.06.004     Document Type: Article

References (50)

1. Møller C.H., Gustafsson F., Gluud C., Steinbrüchel D.A. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: Systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 2008, 27:835-842.
2. Castellaneta A., Thomson A.W., Nayyar N., de Vera M., Mazariegos G.V. Monitoring the operationally tolerant liver allograft recipient. Curr Opin Organ Transplant 2010, 15:28-34.
3. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transpl 2007, 21:149-158.
4. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004, 4:169-177.
5. Falagas M.E., Snydman D.R., Griffith J., Ruthazer R., Werner B.G. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997, 126:275-279.
6. Slifkin M., Ruthazer R., Freeman R., Bloom J., Fitzmaurice S., Fairchild R., et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transplant 2005, 11:1597-1602.
7. Falagas M.E., Snydman D.R., Ruthazer R., Griffith J., Werner B.G., Freeman R., et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transpl 1997, 11:432-437.
8. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transplant 2008, 14:S36-S44.
9. Wiesner R.H., Demetris A.J., Belle S.H., Seaberg E.C., Lake J.R., Zetterman R.K., et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998, 28:638-645.
10. Tippner C., Nashan B., Hoshino K., Schmidt-Sandte E., Akimaru K., Böker K.H., et al. Clinical and subclinical acute rejection early after liver transplantation: Contributing factors and relevance for the long-term course. Transplantation 2001, 72:1122-1128.
11. Almenar Bonet L. 20th Official Report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2008). Rev Esp Cardiol 2009, 62:1286-1296. Spanish Heart Transplantation Registry.
12. Charlton M., Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C. Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transplant Surg 1999, 5:S107-S114.
13. McTaggart R.A., Terrault N.A., Vardanian A.J., Bostrom A., Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transplant 2004, 10:975-985.
14. Berenguer M., Prieto M., Córdoba J., Rayón J.M., Carrasco D., Olaso V., et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998, 28:756-763.
15. Everson G.T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transplant 2002, 8:S19-S27.
16. Regev A., Molina E., Moura R., Bejarano P.A., Khaled A., Ruiz P., et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transplant 2004, 10:1233-1239.
17. García-Alonso A.M., Minguela A., Muro M., Ontañón J., Torío A., Marín L., et al. CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant: Up-regulation in acute rejection. Hum Immunol 1997, 53:64-72.
18. Minguela A., Marín L., Torío A., Muro M., García-Alonso A.M., Moya-Quiles M.R., et al. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum Immunol 2000, 61:658-669.
19. Minguela A., Miras M., Bermejo J., Sánchez-Bueno F., López-Álvarez M.R., Moya-Quiles M.R., et al. HBV and HCV infections and acute rejection differentially modulate CD95 and CD28 expression on peripheral blood lymphocytes after liver transplantation. Hum Immunol 2006, 67:884-893.
20. Linsley P.S., Ledbetter J.A. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993, 11:191-212.
21. Pita-Lopez M.L., Gayoso I., DelaRosa O., Casado J.G., Alonso C., Muñoz-Gomariz E., et al. Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors. Immun Ageing 2009, 6:11.
22. + CD27- T cells: The potential involvement of interleukin-7 in this process. Immunology 2011, 132:326-339.
23. Wallace D.L., Masters J.E., De Lara C.M., Henson S.M., Worth A., Zhang Y., et al. Human cytomegalovirus-specific CD8(+) T-cell expansions contain long-lived cells that retain functional capacity in both young and elderly subjects. Immunology 2011, 132:27-38.
24. Tarazona R., Delarosa O., Alonso C., Ostos B., Espejo J., Peña J., et al. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 2000, 121:77-88.
25. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
26. + T cells recuperation. Transplantation 2009, 88:S54-S61.
27. Stewart S., Winters G.L., Fishbein M.C., Kobashigawa H.J., Abrams J., Andersen C.B., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005, 24:1710-1720.
28. Mor E., Solomon H., Gibbs J.F., Colman M.J., Goldstein R.M., Husberg B.S., et al. Acute cellular rejection following liver transplantation: Clinical pathologic features and effect on outcome. Semin Liver Dis 1992, 12:28-40.
29. Barten M.J., Rahmel A., Boldt A., Dhein S., Bittner H.B., Tarnok A., et al. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: Whole blood flow cytometric analysis of lymphocyte function. Comput Biol Med 2007, 37:1367-1373.
30. Martínez-Llordella M., Lozano J.J., Puig-Pey I., Orlando G., Tisone G., Lerut J., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857.
31. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
32. + adenosine triphosphate activity in a liver transplant cohort: Insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transplant 2008, 14:1313-1322.
33. + T-cells a predictive biomarker of immune status in stable transplant recipients?. Transplantation 2009, 88:S78-S84.
34. Van Bergen J., Thompson A., Van Der Slik A., Ottenhoff T.H., Gussekloo J., Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004, 173:6719-6726.
35. Vivier E., Anfossi N. Inhibitory NK-cell receptors on T cells: Witness of the past, actors of the future. Nat Rev Immunol 2004, 4:190-198.
36. Speiser D.E., Valmori D., Rimoldi D., Pittet M.J., Liénard D., Cerundolo V., et al. CD28-negative cytolytic effector T-cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999, 29:1990-1999.
37. Colovai A.I., Mirza M., Vlad G., Wang S., Ho E., Cortesini R., et al. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 2003, 64:31-37.
38. Manavalan J.S., Kim-Schulze S., Scotto L., Naiyer A.J., Vlad G., Colombo P.C., et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004, 16:1055-1068.
39. Anfossi N., Doisne J.M., Peyrat M.A., Ugolini S., Bonnaud O., Bossy D., et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol 2004, 173:7223-7229.
40. Van Der Veken L.T., Campelo M.D., Van Der Hoorn M.A., Hagedoorn R.S., van Egmond H.M., van Bergen J., et al. Functional analysis of killer Ig-like receptor-expressing cytomegalovirus-specific CD8+ T cells. J Immunol 2009, 182:92-101.
41. Anfossi N., Pascal V., Vivier E., Ugolini S. Biology of T memory type 1 cells. Immunol Rev 2001, 181:269-278.
42. Vely F., Peyrat M., Couedel C., Morcet J., Halary F., Davodeau F., et al. Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J Immunol 2001, 166:2487-2494.
43. Raulet D.H., Vance R.E., McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
44. Li H., Pascal V., Martin M.P., Carrington M., Anderson S.K. Genetic Control of variegated KIR gene expression: Polymorphisms of the bi-direccional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet 2008, 4;:e1000254.
45. Gumá M., Angulo A., López-Botet M. NK cell receptors involved in the response to human cytomegalovirus infection. Curr Top Microbiol Immunol 2006, 298:207-223.
46. Welte S.A., Sinzger C., Lutz S.Z., Singh-Jasuja H., Sampaio K.L., Eknigk U., et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003, 33:194-203.
47. Zou Y., Bresnahan W., Taylor R.T., Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 2005, 174:3098-3104.
48. Miller D.M., Zhang Y., Rahill B.M., Waldman W.J., Sedmak D.D. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J Immunol 1999, 162:6107-6113.
49. Hadaya K., de Rham C., Bandelier C., Bandelier C., Ferrari-Lacraz S., Jendly S., et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 2008, 8:2674-2683.
50. Domínguez-Villar M., Muñoz-Suano A., Anaya-Baz B., Aguilar S., Novalbos J.P., Giron J.A., et al. Hepatitis C virus core protein up-regulates anergy-related genes and a new set of genes, which affects T cell homeostasis. J Leukoc Biol 2007, 82:1301-1310.